START FREE TRIAL
Home Healthcare Incyte Corporation

Incyte Corporation

$19.00

SKU: INCY-1 Category:

Description

Incyte’s Vega Therapeutics Acquisition: A Pivotal Move Beyond Jakafi!

 

Incyte Corporation reported third quarter 2026 results showcasing a 14% year-over-year increase in total revenue to $1.56 billion, driven primarily by broad-based growth across its core business and late-stage pipeline advancement. Net sales reached $1.32 billion, with Jakafi continuing to be a significant contributor at $827 million, reflecting 4% growth despite pricing pressures tied to CMS’s GENEROUS Model. Underlying demand for Jakafi increased 12% across all indications, led by polycythemia vera. The company noted encouraging progress in its core business excluding Jakafi, which grew 30% to $490 million, bolstered by key franchises such as OPZELURA, NIKTIMVO, ZYNYZ, and MONJUVI. OPZELURA sales in particular rose 36% year-over-year to $255 million, supported by expanded formulary coverage and rising U.S. demand. Incyte is advancing several late-stage clinical programs targeting hematology and oncology indications.